• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial

byMatthew Lin, MDandShaidah Deghan, MSc. MD
September 1, 2016
in Chronic Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The rate of adverse asthma-related events was similar in patients with asthma treated with fixed-dosed salmeterol-fluticasone therapy compared to fluticasone monotherapy.

2. The mean percentage of rescue therapy-free days was similar in patients with asthma that were treated with fixed-dosed salmeterol-fluticasone therapy compared to fluticasone monotherapy.

Evidence Rating Level: 1 (Excellent)
­

Study Rundown: In adults, long-acting beta-agonists (LABAs) have been associated with an increased risk of asthma-related death. However, recent data on adolescents has demonstrated that LABA usage in a fixed-dose combination with an inhaled glucocorticoid does not increase the risk of adverse asthma-related events compared to inhaled glucocorticoid monotherapy. Additionally, recent meta-analyses have shown that combined LABA and inhaled glucocorticoid usage in pediatric patients reduced the risk of hospitalization. In this study, researchers aimed to prospectively determine whether fluticasone-salmeterol was superior to fluticasone alone with regards to adverse asthma-related events (i.e. hospitalization, intubation, death). Their results demonstrated that the rate of adverse asthma-related events was similar in patients treated with salmeterol-fluticasone and fluticasone only. Their data also showed that the mean percentage of rescue therapy-free days was similar in patients receiving fluticasone-salmeterol and fluticasone only. Their study is limited by its short duration of 6 months and the relatively infrequent occurrence of adverse asthma-related events.

Click to read the study, published today in NEJM

Relevant Reading: Safety of long-acting β agonists for the treatment of asthma: clearing the air

In-Depth [randomized controlled trial]: In this randomized, double-blind, active-comparator trial, children between the ages of 4-11 years of age (n = 6208) were randomized to receive either fluticasone-salmeterol therapy (n = 3107) or fluticasone monotherapy (n = 3101) for 26 weeks. The primary outcome was first adverse asthma-related event (i.e. death, intubation, hospitalization). Of the 6208 patients, 27 (0.9%) in the fluticasone-salmeterol group and 21 (0.7%) met the composite safety end point, with a HR 1.28 (95%CI 0.72-2.27; p=0.006). All adverse asthma-related events were hospitalizations – there were no asthma-related deaths or intubations. In the fluticasone-salmeterol and fluticasone only group, 265 (8.5%) and 309 (10%) patients had one or more severe asthma exacerbations, respectively, with a HR 0.86 (95%CI 0.73-1.01). In a subgroup analysis, the number of patients who had a severe asthma exacerbation was 25% lower in patients who continued on combination therapy compared to those who had LABA withdrawn (7.5% vs. 9.9%; HR 0.75; 95%CI 0.57-0.98). The mean percentage of rescue therapy-free days was 83% and 81.9% in the salmeterol-fluticasone and fluticasone only groups. Additionally, the mean percentage of days with controlled asthma was also similar – with 74.7% in the combination therapy group and 73.4% in the fluticasone monotherapy group.

RELATED REPORTS

Tiotropium bromide safe and effective in treating early childhood wheezing

Pediatric asthma morbidity is associated with geographic location and social determinants of health

Comparison of systemic corticosteroids with and without nebulized budenoside for management of severe acute asthma

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthma
Previous Post

Early ART therapy for HIV-1 linked to decreased transmission: The HPTN 052 trial

Next Post

Exercise associated with reduced risk of C-section

RelatedReports

Hypertonic saline may be effective in bronchiolitis
Chronic Disease

Tiotropium bromide safe and effective in treating early childhood wheezing

August 16, 2022
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Pediatric asthma morbidity is associated with geographic location and social determinants of health

August 15, 2022
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Emergency

Comparison of systemic corticosteroids with and without nebulized budenoside for management of severe acute asthma

August 3, 2022
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Emergency

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

June 21, 2022
Next Post
Reduced gestational weight gain with lifestyle intervention

Exercise associated with reduced risk of C-section

USPSTF recommends biennial screening mammography in 50 to 74 year-old women

2 Minute Medicine Rewind September 5, 2016

Hypoxia biomarker may predict distant recurrence in pancreatic cancer

Protein identified for detecting and targeting pancreatic adenocarcinoma [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]
  • #VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
  • Tiotropium bromide safe and effective in treating early childhood wheezing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.